References
Allegaert K, van den Anker J. Neonatal drug therapy: the first frontier of therapeutics for children. Clin Pharmacol Ther. 2015;98:288–97.
Turner MA, Duncan JC, Shah U, Mestvaht T, Varendi H, Nellis G, et al. Risk assessment of neonatal excipient exposure: lessons from food safety and other areas. Adv Drug Deliv Rev. 2014;73:89–101.
Nellis G, Metsvaht T, Varendi H, Lass J, Duncan J, Nunn AJ, et al. Product substitution as a way forward in avoiding potentially harmful excipients in neonates. Pediatr Drugs. 2016. doi:10.1007/s40272-016-0173-5.
Institute for Safe Medication Practices. Medication Safety Alert, February 13, 2014. Survey links PN component shortages to adverse outcomes. http://www.ismp.org/newsletters/acutecare/showarticle.aspx?id=70. Accessed 11 Apr 2016.
Klingmann V, Seitz A, Meissner T, Breitkreutz J, Moeltner A, Bosse HM. Acceptability of uncoated mini-tablets in neonates-a randomized controlled trial. J Pediatr. 2015;167:893–96e2.
Salunke S, Brandys B, Giacoia G, Tuleu C. The STEP (Safety and Toxicity of Excipients for Paediatrics) database: part 2—the pilot version. Int J Pharm. 2013;457:310–22.
Salunke S, Tuleu C, European Paediatric Formulation Initiative (EuPFI). The STEP database through the end-users eyes-USABILITY STUDY. Int J Pharm. 2015;492:316–31.
Kulo A, de Hoon JN, Allegaert K. The propylene glycol research project to illustrate the feasibility and difficulties to study toxicokinetics in neonates. Int J Pharm. 2012;435:112–4.
Turner MA, Duncan J, Shah U, Metsvaht T, Varendi H, Nellis G, et al. European study of neonatal exposure to excipients: an update. Int J Pharm. 2013;457:357–8.
De Cock RF, Allegaert K, Vanhaesebrouck S, de Hoon J, Verbesselt R, Danhof M, et al. Low but inducible contribution of renal elimination to clearance of propylene glycol in preterm and term neonates. Ther Drug Monit. 2014;36:278–87.
Pandya HC, Mulla H, Hubbard M, Cordell RL, Monks PS, Yakkundi S, et al. Essential medicines containing ethanol elevate blood acetaldehyde concentrations in neonates. Eur J Pediatr. 2016. doi:10.1007/s00431-016-2714-x.
Schmitt G. Safety of excipients in pediatric formulations—a call for toxicity studies in juvenile animals ? Children. 2015;2:191–7.
Lau K, Swiney BS, Reeves N, Noguchi KK, Farber NB. Propylene glycol produces excessive apoptosis in the developing mouse brain, alone and in combination with phenobarbital. Pediatr Res. 2012;71:54–62.
Acknowledgments
The clinical research of K Allegaert was supported by the Fund for Scientific Research, Flanders (fundamental clinical investigatorship 1800214N) and the research activities are further facilitated by the agency for innovation by Science and Technology in Flanders (IWT) through the SAFEPEDRUG project (IWT/SBO 130033).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
K. Allegaert and I. Spriet declare that they have no relevant conflicts of interest.
Source of funding
No sources of funding were used to support the writing of this manuscript.
Rights and permissions
About this article
Cite this article
Allegaert, K., Spriet, I. Substitution as a Strategy to Improve Excipient Exposure in Neonates: One Piece of the Puzzle. Pediatr Drugs 18, 231–233 (2016). https://doi.org/10.1007/s40272-016-0178-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40272-016-0178-0